Osmolex ER (Amantadine HCl) Patent Expiration, LOE Window & CMS Spending
Osmolex ER (Amantadine HCl) by Supernus/Adamas: FDA Orange Book LOE 2038-02-15, 16 AB generics, $345K 2024 CMS Part D & Medicaid spend, and 4 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Supernus/Adamas |
| FDA Application & Pathway | N209410 (NDA) |
| Exclusivity / Cliff Horizon | Long-Dated Protection (2036+) |
| Core Active-Ingredient LOE Date | Not listed / N/A |
| Last Listed Patent or Exclusivity Date | 2038-02-15 |
| Orange Book Patents (*PED Extensions) | 9 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 16 |
| 2024 CMS Total Public Spend | $345K |
| 2024 Medicare Part D Spend | $328K |
| 2024 Medicaid Spend | $16K |
| Reported Wholesale Price Change (CA SB 17) | 4 WAC filings (max 32.7% 2-yr change) |